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H I G H L I G H T S
• Neurodegenerative diseases show different atrophy patterns on MRI.• Voxel-based volumetry of 360 healthy controls and 120 patients with different dementia was performed.• Dementia could be differentiated from normal ageing with high accuracy.• Diagnostic accuracy is raised by investigating both grey matter and cerebrospinal fluid rather than grey matter only.
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A B S T R A C T
Purpose: Previous studies showed voxel-based volumetry as a helpful tool in detecting pathologic brain atrophy.
Aim of this study was to investigate whether the inclusion of CSF volume improves the imaging based diagnostic
accuracy using combined automated voxel- and region-based volumetry.
Methods: In total, 120 individuals (30 healthy elderly, 30 frontotemporal dementia (FTD), 30 Alzheimer’s de-
mentia (AD) and 30 Lewy body dementia (LBD) patients) were analyzed with voxel-based morphometry and
compared to a reference group of 360 healthy elderly controls. Abnormal GM and CSF volumes were visualized
via z-scores. Volumetric results were finally evaluated by ROC analyses.
Results: Based on the volume of abnormal GM and CSF voxels high accuracy was shown in separating dementia
from normal ageing (AUC 0.93 and 0.91, respectively) within 5 different brain regions per hemisphere (frontal,
medial temporal, temporal, parietal, occipital). Accuracy for separating FTD and AD was higher based on CSF
volume (FTD: AUC 0.80 vs. 0.75 in frontal regions; AD: AUC 0.78 vs. 0.68 in parietal regions based on CSF and
GM respectively).
Conclusions: Differentiation of dementia patients from normal ageing persons shows high accuracy when based
on automatic volumetry alone. Evaluating volumes of abnormal CSF performed better than volumes of abnormal
GM, especially in AD and FTD patients.
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1. Introduction
According to the German S3-Guideline Dementia (AWMF-Register-
Number: 038-013) a cranial CT or MRI should be performed to exclude
secondary causes such as tumor, subdural hemorrhage or hydro-
cephalus, and to contribute in differentiation of neurodegenerative
disorders. For completing the first task, a CT is considered as sufficient.
For the differentiation of neurodegenerative diseases, especially in
clinically unclear cases and younger patients, MRI is more favorable,
since different pathologies such as Alzheimer’s dementia (AD), fronto-
temporal dementia (FTD) and Lewy body dementia (LBD) show dif-
ferent atrophy pattern (Wippold et al., 2015).
When including depressive pseudodementia, treatable causes are
found in up to 30% of patients (Djukic et al., 2015; Muangpaisan et al.,
2012). Especially in these cases MRI might be a helpful tool to prove or
exclude brain atrophy. Although published results show that visual
Fig. 1. Voxels with abnormal z-scores superimposed in dark to light blue (=GM-volume loss) and red to yellow (=CSF-volume increase) onto the individual 3D-T1w-
MRI. (A) HC (65F) without relevant cortical atrophy. (B) AD patient (71F) with typical medial temporal and parietal volume changes. (C) AD patient (72 M) with no
atrophy within the medial temporal structures but significant CSF-volume increase within the parietal region. (D) FTD patient (52 M) with left temporopolar
dominant atrophy. (E) DLB patient (74 M) with no pathognomonic atrophy pattern. (F) Template of one hemisphere depicted from a medial projection. Overview of
the analyzed regions summarized using the LPBA 40 atlas to be comparable with the visual rating scales: frontal in blue, medial temporal in red, temporal in yellow,
parietal in orange and occipital in green. CVR, combined voxel and region based; AD, Alzheimer’s disease; GM, gray matter, CSF, cerebro spinal fluid.
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rating as well as automated voxel-wise volumetric approaches hold
diagnostic potential (Möller et al., 2014; Klöppel et al., 2015; Huppertz
et al., 2016), diagnostic accuracy of MRI is rather low in daily clinical
practice. One primary reason might be the lack of sensitivity and spe-
cificity of visual atrophy rating, even when established visual rating
scales are applied (Davies et al., 2006; Scheltens et al., 1992; Koedam
et al., 2011). Other reasons are a long post-processing time and a not
standardized presentation of automated volumetric results (Frisoni
et al., 2017). One of the most common used automated MRI post-pro-
cessing approaches is Voxel-Based Morphometry (VBM) using Statis-
tical Parametric Mapping (SPM) software (Ashburner, 2012). VBM is a
method in which usually 3D T1-weighted MR images are transformed
into a common space to get rid of the variability in brain anatomy
among individuals. Before comparing brain volumes, data must be
corrected for physiological differences such as head size, gender and
age. Based on this principle, VBM has become a promising and well
established biomarker in the differentiation of neurodegenerative dis-
eases with respect to gray matter volume loss (Frisoni et al., 2017;
Meeter et al., 2017; Saeed et al., 2017). VBM is methodologically suf-
ficient for the classification of GM and WM as well as for clinical use.
The evaluation was carried out several times with the result that the
VBM is reproducible and stable and thus established as a standard
method (Huppertz et al., 2010; Kazemi and Noorizadeh, 2014;
Fellhauer et al., 2015).
Although visual rating scales are considered to evaluate gray matter
volume loss, they are more or less based on the evaluation of widening
of the corresponding brain sulci (Harper et al., 2016). We therefore
hypothesized that the diagnostic accuracy in detecting region-specific
pathologic brain atrophy can be improved by including voxel-wise
evaluation of CSF volume into a volumetric MRI post-processing ap-
proach.
Therefore, aim of this study was to investigate the diagnostic ac-
curacy in differentiating between dementia patients and healthy con-
trols, as well as to differentiate between common primary dementia
disorders by using combined voxel- and region-based (CVR) analyses of
GM volume decrease and CSF volume increase.
2. Results
Human rating did only reach moderate accuracy in differentiating
dementia patients from healthy controls with respect to medial tem-
poral and parietal regions (AUC 0.79 and 0.71).
In differentiating the entities from each other, there was only
moderate accuracy, too.
Low visual rating scores in the frontal (AUC 0.75) and temporal
(AUC 0.73) regions were pathognomonic forFTD, while AD was de-
limited through medial temporal (AUC 0.76) and parietal (AUC 0.73)
atrophy (Fig. 4).
2.1. Dementia versus normal aging
Receiver operating characteristic (ROC) analyses showed a high
diagnostic accuracy when decreased GM volumes (z-score < −2) of
the medial temporal lobes (area under the curve (AUC) 0.93) and of the
temporal lobes (AUC 0.91) were considered. Diagnostic accuracy was
lower, when the parietal (AUC 0.86), frontal (AUC 0.84) and occipital
lobes (AUC 0.83) were considered, respectively (Fig. 2).
With respect to the CSF volume increase (z-score > 2) diagnostic
accuracy was high for medial temporal regions (AUC 0.91) and mod-
erate for temporal (AUC 0.84), parietal (AUC 0.84), frontal (AUC 0.73)
and occipital regions (AUC 0.73) (Fig. 3). Based on these ROC curves, a
sensitivity of 0.81 and specificity of 0.97 with respect to the GM vo-
lume, and a sensitivity of 0.83 and specificity of 0.9 with respect to the
CSF volume within the medial temporal region was calculated.
Given the phenotypical variability of AD patients, atypical cases
such as posterior atrophy (PA) were identified via a CSF volume
increase in the parietal lobes while medial temporal regions showed
normal GM and CSF volumes.
2.2. FTD versus rest
ROC analyses revealed a moderate diagnostic accuracy with respect
to the GM volume in temporal (AUC 0.78) and frontal regions (AUC
0.75). Corresponding values for the CSF volume were 0.81 and 0.8,
respectively. Sensitivity and specificity for the temporal regions were
0.77 and 0.73 (GM volume) and 0.8 and 0.74 (CSF volume), respec-
tively (Figs. 2 and 3).
2.3. AD versus rest
ROC analyses revealed a low accuracy when the GM volumes of the
parietal lobes (AUC 0.67) and a moderate accuracy (AUC 0.78) when
the CSF volumes were considered. This resulted in a sensitivity and
specificity of 0.93 and 0.48 based on the GM volume and 0.73 und 0.76
for the CSF volume in parietal regions, respectively. Frontal and tem-
poral regions showed low accuracy considering GM (AUC 0.67 and
0.65) with moderate accuracy using CSF (AUC 0.75 and 0.71) (Figs. 2
and 3).
2.4. LBD versus rest
ROC analyses of GM and CSF z-score-volumes showed a low accu-
racy with a maximum AUC of 0.58 and 0.55 in medialtemporal regions,
quite close to chance level. The other regions have an even lower AUC
(Figs. 2 and 3).
3. Discussion
Most previous VBM studies primarily assessed regional GM volume
loss. In contrast, visual rating is typically based on defining abnormal
regional widening of cortical sulci (Davies et al., 2006; Scheltens et al.,
1992; Koedam et al., 2011). Here, we included information about the
intracranial CSF volume into a VBM analysis in order to improve the
diagnostic accuracy, especially to identify AD and FTD patients (Fig. 1).
After optimizing the threshold settings as visualized in the ROC
curve (Figs. 2 and 3) the high true positive (TPR = sensitivity) and low
false positive rates (FPR = 1-specificity) prove this analysis suited to
detect and exclude abnormal brain volume conditions just by using the
z-score-analysis output. Especially when separating AD and FTD pa-
tients from the remaining cohort, the additional CSF volume analysis of
the parietal region in AD and frontal and temporal regions in FTD in-
creased the diagnostic accuracy (Figs. 1 and 3). This approach surpasses
human performance based on established visual rating scales.
Parietal atrophy is common in AD: In a former study, 28% of AD
patients had prominent parietal atrophy without evident medial tem-
poral lobe atrophy (MTA). Combining visual rating scales for MTA and
posterior cortical atrophy increased the sensitivity to identify AD pa-
tients from around 50% to 73% (Koedam et al., 2011).
Rating of MTA and PA is mainly based on an increase of the CSF
compartment. In the MTA score, first signs for atrophy of medial tem-
poral structures are widening of the choroidal fissure and the temporal
horn (Scheltens et al., 1992). The PA score is based on widening of the
parietal sulci including the posterior cingulate and the parieto-occipital
sulci evaluated in three different planes (Koedam et al., 2011). Current
studies describe atrophies in both regions as pathognomonic for AD
diagnosis (Frenzel et al., 2020; Cajanus et al., 2018; Hedderich et al.,
2020; Cavedo et al., 2017; Persson et al., 2017).
Regarding FTD different quantification methods including VBM and
region-based GM volumetry are established. A decision support tool
named Disease State Index was used as statistical classifier. By using
GM volumes of various brain areas and VBM, a classification sensitivity
of up to 60% for the whole FTD cohort was achieved (Cajanus et al.,
K. Egger, et al. Brain Research 1739 (2020) 146800
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2018). This result is in accordance with our study regarding FTD clas-
sification when restricted to GM volume. However, with additional CSF
volume analysis the sensitivity increased up to 93% (Fig. 3).
LBD patients were poorly identified with automated volumetry,
regardless if CSF volume analysis was included or not. This is consistent
with the existing literature and primarily due to the fact, that LBD is
associated with only minimal volume changes on structural MRI as
shown in autopsy confirmed cases (Nedelska et al., 2015).
Inter-scanner variability is considered a limitation for automated
structural MRI based diagnostic decision support tools. However, this is
mainly a problem in monitoring subtle longitudinal intra-individual
volume changes (Huppertz et al., 2010). Since it is quite impossible to
collect enough scans for preparing hard- and software-specific reference
groups, we decided to include images from different scanners with
different magnetic field strengths as well as to include images from the
Alzheimer’s Disease Neuroimaging Initiative cohort. However, the
availability of fast and reliable automated volumetric results as well as
the additional effort for supporting the IT-infrastructure might be lim-
iting factors for the region wide implementation into diagnostic rou-
tine. Therefore, institutional networking might help. As in our specific
CVR volumetric algorithm, the total analysis time is about 10 min per
case and via already existing secured internet connections images and
volumetric results can be shared in a standardized way with relatively
low effort.
4. Conclusion
The focus of most volumetric studies is primarily on GM volume
loss. In contrast, visual rating is typically based on defining abnormal
widening of specific cortical sulci. Therefore, we added information on
global intracranial CSF volume into the automated CVR-volumetric
analyses and could therefore improve the diagnostic accuracy espe-
cially in AD as well as FTD patients.
Fig. 2. ROC analyses based on GM CVR volumetry. ROC analyses based on the volume of voxels with z-score < −2 within the GM of frontal regions (red), medial
(mesio) temporal regions (green), occipital regions (black), parietal regions (orange), temporal regions (gray). Maximum sensitivity (opt. sen.) and maximum
specificity (opt. spe.) is shown as small circle on the corresponding curve representing the intercept with a 45 degree line closest to the error-free point (0.1). ROC,
receiver operating characteristic; CVR, combined voxel and region based; GM, gray matter; HC, healthy control; FTD, frontotemporal dementia; AD, Alzheimer’s
disease; LBD, Lewy body dementia; AUC, area under the curve; opt. sen, optimized sensitivity; opt. spe., optimized specificity.
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5. Methods
5.1. Study cohort
In total, 120 participants were acquired in Freiburg, Munich, and
Leipzig and included in this retrospective study. The study population
comprised 30 patients with AD, 30 patients with FTD, 30 patients with
LBD and 30 healthy controls (HC) with a minimum age of 60 years,
respectively. Demographic and clinical data are given in Table 1. In
order to avoid a confound between diagnostic category and scanning
parameters, ten cases with AD, LBD, ten controls, and six cases with
FTD were provided from Freiburg with comparable scanning para-
meters and supplemented with external data to fill each category.
Participants from all diagnostic groups showed clinical and biomarker
patterns (including 18F-FDG PET) consistent with their respective di-
agnosis according to established criteria. Specifically, HC were included
if their Montreal Cognitive Assessment (MoCA) score was ≥26
(Nasreddine et al., 2005) and their Beck’s Depression Inventory-II (Beck
et al., 1996) was ≤13. This retrospective study was carried out in ac-
cordance with the latest update of the Declaration of Helsinki. HC MRI
scans were approved by the local Medical Ethics Review Committee.
5.2. Image acquisition
Sagittal T1-weighted 3D magnetization prepared rapid gradient
echo (MPRAGE) sequences (approximately 1 × 1 × 1 mm3 resolution)
were acquired on different types of 1.5 and 3 Tesla Siemens scanners,
each with a standard head coil (TR 2300–3000 ms, TE 2.86–4.0 ms, FA
8-9°, TI 900–1000 ms). The MPRAGE sequences were converted to
NIfTI-2 format, and the filenames were pseudonymized before further
processing.
Fig. 3. ROC-analyses based on CSF CVR volumetry. ROC analyses based on the volume of voxels with z-score > 2 within the CSF space next to frontal regions (red),
medial (mesio) temporal regions (green), occipital regions (black), parietal regions (orange), temporal regions (gray). Maximum sensitivity (opt. sen.) and maximum
specificity (opt. spe.) is shown as small circle on the corresponding curve representing the intercept with a 45 degree line closest to the error-free point (0.1). ROC,
receiver operating characteristic; CVR, combined voxel and region based; CSF, cerebro spinal fluid; HC, healthy control; FTD, frontotemporal dementia; AD,
Alzheimer’s disease; LBD, Lewy body dementia; AUC, area under the curve; opt. sen, optimized sensitivity; opt. spe., optimized specificity.
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5.3. Visual rating
Visual rating was performed blinded for diagnoses. Atrophy in ten
regions had to be rated on a three level scale (0 = normal; 1 = bor-
derline atrophy; 2 = pathological atrophy). Medial temporal atrophy
was adapted from the medial temporal atrophy score proposed by
Scheltens et al. (1992). The parietal atrophy rating followed the rating
proposed by Koedam et al. (2011). Frontal and lateral temporal atrophy
was rated following Davies et al. (2006). Occipital atrophy was eval-
uated concordant to the previously mentioned rating scales, since no
standardized rating scale has been developed so far.
Fig. 4. ROC analyses of human rating based on established visual rating scales regarding frontal regions (red), medial (mesio) temporal regions (green), occipital
regions (black), parietal regions (orange), temporal regions (gray). Maximum sensitivity (opt. sen.) and maximum specificity (opt. spe.) is shown as small circle on
the corresponding curve representing the intercept with a 45 degree line closest to the error-free point (0.1).
Table 1
Sociodemographic characterization of the study cohorts.
Healthy controls Alzheimer’s disease Lewy-body dementia Frontotemporal dementia
Mean SD Mean SD Mean SD Mean SD
n (m/f) 13/17 14/16 14/16 11/19
Age (years) 72.4 4.4 71.6 7.4 72.2 7.7 65.7 7.8
Education (years) 16.7 2.9 14.8 2.4 10.9 2.4 11.1 3.7
MMSE 29.0 1.5 23.2 3.2 22.1 3.2 22.8 3.4
Note: SD = standard deviation, MMSE = Mini Mental Status Examination.
For n = 6, no MMSE was available but cognitive functioning was evaluated with the Montreal Cognitive Assessment (MoCA). MoCA scores were converted into
MMSE scores according to Trzepacz et al. (2015).
K. Egger, et al. Brain Research 1739 (2020) 146800
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5.4. Image processing
5.4.1. Estimation of normalized local volumes
360 healthy controls (HC) were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (Weiner et al., 2010).
As in patients the age of the healthy controls ranged from 55 to
90 years. All T1 weighted images were segmented into GM, WM and
CSF and non-linear transformed to MNI space by using the segmenta-
tion algorithm of SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/
spm12). The default setting was used for processing and the modulated
warped tissues were selected as outputs. These normalized and modu-
lated images were then smoothed with a Gaussian filter of 3x3x3 mm
FHWM. The quantity of GM and CSF volume was adjusted linearly for
effects of age, sex and total intracranial volume by using ordinary least
squares estimation of regression parameters and the residual variance
as estimate of uncertainty.
5.4.2. Calculation of atrophy scores
MRI data from all 120 study participants were processed analogous
to the reference group with additional forward and inverse DARTEL
transformation as outputs. The GM/CSF volumes were subtracted from
the measured volume of 360 healthy controls. The atrophy scores
αGM(v,s) and αCSF(v,s) for GM and CSF in MNI space were defined as:
= xy s vv( ,s) ( ,s)
where s indicate the subject and ν voxel location. y is the measured
local volume of GM or CSF, χ the predictors of age, sex and intracranial
volume. is the estimated parameters of the linear model, the esti-
mated residual variance. These scores as map in MNI space were non-
linear transformed back to native space. We used a threshold of −2 for
GM and 2 for CSF to display the atrophy scores, also called z-scores. The
z-scores of CSF larger than 2 were displayed from red to yellow. The
scores of GM less than −2 were were displayed from dark blue to light
blue (see Fig. 1). The clusters of less than five voxels were removed
from the map.
5.5. Evaluation and statistical analysis
Each of our 4 diagnoses was compared against the rest. To test for
the diagnostic accuracy based on z-scores alone, we used the LPBA40
atlas (Shattuck et al., 2008) to define 10 regions of interest (ROI) (5 per
hemisphere), covering frontal lobe, medial temporal structures (hip-
pocampus, parahippocampal gyrus, entorhinal cortex), the rest of the
temporal lobe (consecutively named “temporal region” for the sake of
convenience) as well as covering parietal and occipital lobe structures.
The corresponding ROIs were pooled across hemispheres and the mean
z-score values, with the resulting volumes of voxels with abnormal z-
scores (<−2 for GM and>2 for CSF) within these ROIs were calcu-
lated. To define the diagnostic ability of this automated z-score based
analysis, we showed the ROC curve with its resulting AUC as well as the
sensitivity and specificity at optimized threshold settings derived from
the intercept of the ROC curve with the line at 45 degrees closest to the
error free point (0.1). According to an arbitrary guideline, we dis-
tinguished between non-informative (AUC = 0.5), less accurate
(0.5 < AUC > 0.7), moderately accurate (0.7 < AUC > 0.9) and
highly accurate (0.9 < AUC > 1) (Swets, 1988).
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